A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India

Background: Recurrent and clinically unresponsive dermatophytosis is being increasingly encountered in our country. It runs a protracted course with exacerbations and remissions. However, there is little information regarding the extent of the problem and the characteristics of recurrent dermatophytosis in published literature. Aims: We sought to determine the prevalence, risk factors and clinical patterns of recurrent dermatophytosis in our institution. We also investigated the causative dermatophyte species and antifungal susceptibility patterns in these species. Methods: One hundred and fifty patients with recurrent dermatophytosis attending the outpatient department of the Postgraduate Institute of Medical Education and Research, Chandigarh, India were enrolled in the study conducted from January 2015 to December 2015. A detailed history was obtained in all patients, who were then subjected to a clinical examination and investigations including a wet preparation for direct microscopic examination, fungal culture and antifungal susceptibility tests. Results: Recurrent dermatophytosis was seen in 9.3% of all patients with dermatophytosis in our study. Trichophyton mentagrophytes was the most common species identified (36 patients, 40%) samples followed by T. rubrum (29 patients, 32.2%). In-vitro antifungal susceptibility testing showed that the range of minimum inhibitory concentrations (MIC) on was lowest for itraconazole (0.015–1), followed by terbinafine (0.015–16), fluconazole (0.03–32) and griseofulvin (0.5–128) in increasing order. Limitation: A limitation of this study was the absence of a suitable control group (eg. patients with first episode of typical tinea). Conclusion: Recurrence of dermatophytosis was not explainable on the basis of a high (MIC) alone. Misuse of topical corticosteroids, a high number of familial contacts, poor compliance to treatment over periods of years, and various host factors, seem to have all contributed to this outbreak of dermatophytosis in India.

[1]  R. Tilak,et al.  Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center , 2017, Indian journal of dermatology, venereology and leprology.

[2]  P. Criado,et al.  Investigation of superficial mycosis in cutaneous allergy patients using topical or systemic corticosteroids , 2017, International journal of dermatology.

[3]  B. Elewski,et al.  Onychomycosis: Strategies to Minimize Recurrence. , 2016, Journal of drugs in dermatology : JDD.

[4]  A. Sahoo,et al.  Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review , 2016, Indian dermatology online journal.

[5]  S. Dogra,et al.  The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? , 2016, Indian dermatology online journal.

[6]  M. Afshari,et al.  Antifungal susceptibility and virulence factors of clinically isolated dermatophytes in Tehran, Iran , 2016, Iranian journal of microbiology.

[7]  P. Sharma,et al.  Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method , 2015, Indian journal of medical microbiology.

[8]  A. Lakshmanan,et al.  Epidemiological and clinical pattern of dermatomycoses in rural India , 2015, Indian journal of medical microbiology.

[9]  K. Ferreira-Paim,et al.  Identification and antifungal susceptibility of fungi isolated from dermatomycoses , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  P. Sharma,et al.  Epidemiological studies on Dermatophytosis in human patients in Himachal Pradesh, India , 2014, SpringerPlus.

[11]  Y. Bulut,et al.  In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey , 2013, International journal of dermatology.

[12]  L. Vyas,et al.  A Clinicomycological Study of Cutaneous Mycoses in Sawai Man Singh Hospital of Jaipur, North India , 2013, Annals of medical and health sciences research.

[13]  S. Hashemi,et al.  In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran , 2013, Iranian journal of pharmaceutical research : IJPR.

[14]  K. Sarojini,et al.  Clinicomycological Study of 150 Cases of Dermatophytosis in a Tertiary Care Hospital in South India , 2012, Indian journal of dermatology.

[15]  M. Arendrup,et al.  Molecular diagnosis of dermatophyte infections , 2012, Current opinion in infectious diseases.

[16]  M. Friedrich,et al.  Epidemiological trends in skin mycoses worldwide , 2008, Mycoses.

[17]  H. Degreef Clinical Forms of Dermatophytosis (Ringworm Infection) , 2008, Mycopathologia.

[18]  C. Osborne,et al.  Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine , 2005, Antimicrobial Agents and Chemotherapy.

[19]  森本 健介 Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis , 2005 .

[20]  C. Janaki,et al.  Scenario of chronic dermatophytosis: An Indian study , 1997, Mycopathologia.

[21]  Aditya K. Gupta,et al.  In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity , 2003, The British journal of dermatology.

[22]  V. Bindu,et al.  Clinico-mycological study of dermatophytosis in Calicut. , 2002, Indian journal of dermatology, venereology and leprology.

[23]  R. Summerbell,et al.  The dermatophytes , 1995, Clinical microbiology reviews.